NASDAQ: PRTCPuretech Health PLC Stock
$19.61+0.00 (+0%)
Updated Jun 13, 2025
PRTC Price
$19.61
Fair Value Price
N/A
Market Cap
$469.51M
52 Week Low
$13.30
52 Week High
$28.79
P/E
9.34x
P/B
1.13x
P/S
98.62x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.83M
Earnings
$53.51M
Gross Margin
100%
Operating Margin
1,025.31%
Profit Margin
1,108.3%
Debt to Equity
0.47
Operating Cash Flow
-$134M
Beta
0.49
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PRTC Overview
PureTech Health plc is developing medicines for intractable cancers, as well as inflammatory, fibrotic and immunological, lymphatic and gastrointestinal, and neurological and neuropsychological diseases in the U.S. KarXT (to treat schizophrenia and psychosis in Alzheimer's disease) is currently in-market. Under development are a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions, an immunomodulation platform to treat chronic and acute inflammatory disorders, and oral therapies based on defined consortia of bacteria is isolated from the human microbiome. Puretech Health was incorporated in 2015 and is headquartered in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PRTC's potential to beat the market
- PRTC doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PRTC
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important PRTC news, forecast changes, insider trades & much more!
PRTC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PRTC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRTC was unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRTC is good value based on its earnings relative to its share price (9.34x), compared to the US market average (31.36x)
P/E vs Market Valuation
PRTC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more PRTC due diligence checks available for Premium users.
Valuation
PRTC fair value
Fair Value of PRTC stock based on Discounted Cash Flow (DCF)
Price
$19.61
Fair Value
$49.34
Undervalued by
60.26%
PRTC was unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PRTC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
9.34x
Industry
-108.97x
Market
31.36x
PRTC is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
PRTC is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
PRTC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.13x
Industry
4.66x
PRTC is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRTC's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
PRTC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
PRTC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$602.6M
Liabilities
$194.7M
Debt to equity
0.47
PRTC's short-term assets ($386.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRTC's short-term assets ($386.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRTC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PRTC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PRTC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PRTC vs Biotech Stocks
Puretech Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.